The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT
In 2023, 47,731 HCT (20,485 (42.9%) allogeneic and 27,246 (57.1%) autologous) in 43,902 patients were reported by 696 European centers. 6042 patients received advanced cellular therapies, 4888 of which were CAR-T. Compared to the previous year there was an increase in CAR-T (+52.5%), in allogeneic HCT (+7.8%) but none in autologous HCT (+0.4%). Main indications for allogeneic HCT were myeloid (11,748; 60.7%), lymphoid malignancies (4,850; 25.0%), and non-malignant disorders (2558; 13.2%). Use of allogeneic HCT increased for AML (+12.1%) and for NHL (+11.0%), particularly in T-NHL (+25.6%). Main indications for autologous HCT were lymphomas (7890; 32.2%), PCD (14,271; 58.2%), and solid tumors (1608; 6.6%) with recovering numbers for autoimmune diseases. In patients with allogeneic HCT, the use of sibling donors increased by +1.0%, haploidentical donors by +11.7%, and unrelated donors by +11.1%. Cord blood HCT decreased again by -5.4%. Pediatric HCT activity increased slightly (5455; +0.1%) with differences between allogeneic (4111; -0.5%) and autologous HCT (1344: +1.7%). Use of CAR-T increased to a cumulative total of 13,927 patients including patients treated for autoimmune diseases. Overall, numbers show a complete recovery from the pandemic dip with increased cellular therapy at the expense of autologous HCT. Allogeneic HCT activity focuses on myeloid malignancies.
Authors
- Jakob Robert Passweg (ORCID: https://orcid.org/0000-0001-7092-3351)
- Krzysztof Kałwak (ORCID: https://orcid.org/0000-0003-1174-5799)
- Bénédicte Neven (ORCID: https://orcid.org/0000-0001-8941-0935)
- Donal P. McLornan (ORCID: https://orcid.org/0000-0003-1224-091X)
- Raffaella Greco (ORCID: https://orcid.org/0000-0002-6117-5328)
- Helen Baldomero (ORCID: https://orcid.org/0000-0002-6554-483X)
- John A. Snowden (ORCID: https://orcid.org/0000-0001-6819-3476)
- Isabel Sánchez‐Ortega (ORCID: https://orcid.org/0009-0005-5519-9154)
- Ali Bazarbachi (ORCID: https://orcid.org/0000-0002-7171-4997)
- Tobias Alexander (ORCID: https://orcid.org/0000-0003-1193-0097)
- Fabio Ciceri
- Antonio M. Risitano (ORCID: https://orcid.org/0000-0002-4744-5109)
- Zinaida Perić (ORCID: https://orcid.org/0000-0001-9458-8025)
- Mette D. Hazenberg (ORCID: https://orcid.org/0000-0002-5113-0249)
- Diana Averbuch (ORCID: https://orcid.org/0000-0001-9614-7274)
- Emanuele Angelucci (ORCID: https://orcid.org/0000-0002-6512-6080)
- Anna Sureda (ORCID: https://orcid.org/0000-0002-1238-6970)
- Annalisa Ruggeri (ORCID: https://orcid.org/0000-0002-7261-2765)
- Marina Atlija
- Iliana Kleovoulou
- Aleksandra Witaszek
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- University of Rijeka (HR)
- Vita-Salute San Raffaele University (IT)
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- University Hospital of Basel (CH)
- Sanquin (NL)
- Wroclaw Medical University (PL)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Hospital Base (CL)
- Assistance Publique – Hôpitaux de Paris (FR)
- European Society for Blood and Marrow Transplantation (NL)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- Institut Català d'Oncologia (ES)
- Azienda Ospedaliera S.Giuseppe Moscati (IT)
- Ospedale Policlinico San Martino (IT)
- University College London (GB)
- Universitat de Barcelona (ES)
- Charité - Universitätsmedizin Berlin (DE)
- University of Amsterdam (NL)
- American University of Beirut (LB)
Publication Details
- Journal
- Bone Marrow Transplantation
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1038/s41409-025-02524-2
- Citations
- 39
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 40.77
Funders
- Universität Basel
- Vertex Pharmaceuticals
- Jazz Pharmaceuticals